A study of antitumor (phase II) and immunosuppressive effects of ICRF-159 in patients with metastatic melanoma.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010879:Piperazines / Q000627:therapeutic use*; D011929:Razoxane / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D010879:Piperazines; D011929:Razoxane